Eliglustat Tartrate and Larotrectinib Capsules
Determining the interaction of Eliglustat Tartrate and Larotrectinib Capsules and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with eliglustat may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by eliglustat. When the P-gp probe substrate digoxin was given with eliglustat 127 mg twice daily in CYP450 2D6 extensive or intermediate metabolizers and 84 mg twice daily in poor metabolizers, mean digoxin peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 1.7- and 1.5-fold, respectively, compared to digoxin administered alone. MANAGEMENT: Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy. References "Product Information. Cerdelga (eliglustat)." Genzyme Corporation, Cambridge, MA.
Professional:MONITOR: Coadministration with eliglustat may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by eliglustat. When the P-gp probe substrate digoxin was given with eliglustat 127 mg twice daily in CYP450 2D6 extensive or intermediate metabolizers and 84 mg twice daily in poor metabolizers, mean digoxin peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 1.7- and 1.5-fold, respectively, compared to digoxin administered alone.
MANAGEMENT: Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.
- "Product Information. Cerdelga (eliglustat)." Genzyme Corporation, Cambridge, MA.
Generic Name: eliglustat
Brand name: Cerdelga
Synonyms: Eliglustat
Generic Name: larotrectinib
Brand name: Vitrakvi
Synonyms: Larotrectinib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Eliglustat Tartrate-Larotrectinib Oral Solution
- Eliglustat Tartrate-Larotrectinib Sulfate
- Eliglustat Tartrate-Lartruvo
- Eliglustat Tartrate-Larynex
- Eliglustat Tartrate-Laryng-O-Jet
- Eliglustat Tartrate-Laryngesic
- Larotrectinib Capsules-Elinest
- Larotrectinib Capsules-Eliphos
- Larotrectinib Capsules-Eliquis
- Larotrectinib Capsules-Eliquis Starter Pack
- Larotrectinib Capsules-Elitek
- Larotrectinib Capsules-Elixophyllin